Since the beginning of development of monoclonal antibodies (mAb) in the 1980s, they become vastly successful as efficacious and safe therapeutics for a variety of diseases. Today, they represent one of the fastest growing segments in the pharmaceutical industry.Nevertheless, the resources and risks associated with the development of new antibodies are immense and reflected in the low number of only ~ 33 antibodies that have been approved in the US whereas 4 were later withdrawn by the sponsor [1].
展开▼
